Inactive Instrument

Celltrion, Inc. Stock price Korea S.E.

Equities

068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
- KRW 0.00% Intraday chart for Celltrion, Inc.
Sales 2023 2,176B 1.63B Sales 2024 * 3,474B 2.6B Capitalization 37,828B 28.3B
Net income 2023 536B 401M Net income 2024 * 656B 491M EV / Sales 2023 12.9 x
Net cash position 2023 * 97.38B 72.84M Net Debt 2024 * 1,628B 1.22B EV / Sales 2024 * 11.4 x
P/E ratio 2023 *
37.6 x
P/E ratio 2024 *
56.8 x
Employees -
Yield 2023 *
0.2%
Yield 2024 *
0.2%
Free-Float 36.53%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 62 07-04-23
Director of Finance/CFO 49 -
Chairman 66 -
Members of the board TitleAgeSince
Director/Board Member 73 -
Chairman 66 -
Director/Board Member 66 -
More insiders
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
More about the company
  1. Stock
  2. Equities
  3. Stock Celltrion, Inc.
  4. Stock Celltrion, Inc. - Korea S.E.